Target intelligence / Profile preview

Cadherin-related family member 2 (CDHR2)

Target
CDHR2
Molecular classification
Protocadherin (non-clustered), Cadherin superfamily, Cell adhesion molecule, Type I transmembrane protein, Other
01

Overview

Cadherin-related family member 2 (CDHR2) is a non-clustered protocadherin and a member of the cadherin superfamily, acting as a calcium-dependent cell adhesion molecule primarily found in epithelial tissues such as small intestine, colon, liver, testis, and kidney[2][3][4]. CDHR2 is a type I transmembrane protein comprising an extracellular domain with nine tandem cadherin repeats, a single-pass transmembrane domain, and a cytoplasmic tail for protein interactions[3][4]. It is crucial for forming intermicrovillar adhesion links at the tips of microvilli, thereby controlling microvilli organization and brush border architecture, which are essential for epithelial absorption and monolayer integrity[1][3][4]. Loss of CDHR2 disrupts microvillar clustering, compromises junctional complexes (including tight and adherens junctions), reduces junctional tension, and leads to abnormal epithelial cell morphology[1][3][6]. CDHR2 is proposed as a tumor suppressor: its expression is reduced in colon and liver cancer, and its restoration suppresses tumor cell growth by promoting β-catenin recruitment and enforcing contact inhibition[1][3][4]. Additionally, CDHR2 dysfunction has been linked to Crohn’s disease and brush border defects[3]. CDHR2 currently has no known interacting pharmacological agents or mechanisms of drug action directly targeting it.

Other names
PCDH24PCLKCPC-LKCFLJ20124FLJ20383Protocadherin LKCProtocadherin-24PCLCKcadherin-related protein 24
02

Biological functions

Cell-cell adhesionEpithelial brush border differentiationOrganization and packing of microvilliRegulation of epithelial monolayer integrityContact inhibitionTumor suppressionOther
03

Disease associations

Cancer (tumor suppressor in colon and liver cancer)Inflammatory bowel disease (Crohn's disease)Usher syndromeOther
04

Safety considerations

Loss of CDHR2 may impair epithelial barrier integrityLoss may lead to increased epithelial cell motility, abnormal junction morphology, defective wound healing
05

Biomarkers

CDHR2 loss as marker of tumor suppression deficitsReduced CDHR2 in colon/liver cancer cell linesCDHR2 and brush border structure abnormality in Crohn's disease

Beyond the preview

Go deeper on Cadherin-related family member 2 (CDHR2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cadherin-related family member 2 (CDHR2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call